drugset / Trial / NCT05684211
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
RandomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, parallel-group, randomised, A phase IIb clinical trial of efficacy and safety of Ametumumab in combination with anti-PD-1 monoclonal antibody and FOLFIRI versus Ametumumab or Cetuximab in combination with FOLFIRI in patients with RAS wild-type advanced colorectal cancer.
Timeline
- Start
- 2023-01
- Primary completion
- 2023-01
- Completion
- 2023-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ametumumab | Monoclonal antibody | 450 mg/m2 | — |
| Comparator | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Comparator | Toripalimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Background | Rinotecan hydrochloride | Unknown | 180 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 1200 mg/m2 | Intravenous |